Print This Post
Though Aβ-targeted therapies hogged the limelight at this year’s Clinical Trials on Alzheimer’s Disease meeting, held December 4–7 in San Diego, California, a large handful of smaller studies had findings to report, as well. These studies evaluated drugs trained against a variety of targets, including telomerase, serotonin receptors, nuclear receptors, and neurotrophic factors. Some clearly flopped, while others posted positive results that, according to their presenters, justify larger trials.
To get the full lowdown on the results shared at the CTAD Conference – take a look at this article on the Alz Forum Website – https://www.alzforum.org/news/conference-coverage/ctad-early-failures-and-hints-success-small-trials
